Spontaneous platelet aggregation in cerebrovascular disease

Area of Science:

• Neurology
• Hematology
• Vascular Biology

Background:

• Transient ischemic attacks (TIAs) and cerebral infarction are serious neurological events.
• Platelet function plays a critical role in cerebrovascular diseases.
• Understanding platelet behavior in these conditions is crucial for developing effective treatments.

Purpose of the Study:

• To investigate the presence and nature of platelet abnormalities in patients with TIAs or cerebral infarction.
• To explore the mechanisms underlying spontaneous platelet aggregation (SPA) in affected patients.
• To evaluate the therapeutic potential of aspirin in managing SPA and associated clinical symptoms.

Main Methods:

• Assessing in vitro spontaneous platelet aggregation (SPA) in 130 patients with TIAs/cerebral infarction and 80 healthy controls.
• Performing platelet isolation and resuspension experiments to determine the source of SPA.
• Evaluating the effect of adenosine diphosphate (ADP), divalent cations, phentolamine, and adenosine on SPA.
• Assessing the impact of aspirin on SPA and clinical symptoms in affected patients.

Main Results:

• 50 out of 130 patients exhibited SPA, a phenomenon absent in 80 healthy subjects.
• SPA was intrinsic to patient platelets, not dependent on plasma factors.
• SPA platelets showed increased aggregation with ADP and were inhibited by phentolamine and adenosine.
• Aspirin abolished SPA in 50 patients and alleviated recurrent transient blindness and paresthesia.

Conclusions:

• A distinct platelet abnormality, characterized by SPA, is present in a subset of patients with TIAs or cerebral infarction.
• This SPA is an intrinsic platelet defect, potentially contributing to cerebrovascular events.
• Aspirin demonstrates significant efficacy in inhibiting SPA and relieving associated clinical manifestations, highlighting its therapeutic value.